Apellis Pharmaceuticals’ Combination Therapy Approach With APL-3007 & SYFOVRE Might Just Pay Off!

Apellis Pharmaceuticals reported a strong performance for the year ending 2024 but noted some transient headwinds. The company achieved significant revenue growth, particularly from its flagship product SYFOVRE, which is a treatment for geographic atrophy (GA). SYFOVRE generated over $900 million in net sales and performed well in the U.S. market, capturing over 60% of the market share. Apellis emphasized SYFOVRE’s market leadership, underscoring its increasing effectiveness over time and flexible dosing regimen.